Role of metabolism in neurodegenerative disorders.

[1]  M. Hayden,et al.  Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin , 2016, Neuropeptides.

[2]  Xiaoyun Huang,et al.  PI3K/AKT/mTOR/p70S6K Pathway Is Involved in Aβ25-35-Induced Autophagy , 2015, BioMed research international.

[3]  Joon-Yong Cho,et al.  Effect of treadmill exercise on PI3K/AKT/mTOR, autophagy, and Tau hyperphosphorylation in the cerebral cortex of NSE/htau23 transgenic mice , 2015, Journal of exercise nutrition & biochemistry.

[4]  B. Winblad,et al.  mTor mediates tau localization and secretion: Implication for Alzheimer's disease. , 2015, Biochimica et biophysica acta.

[5]  T. Jovin,et al.  Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons , 2015, Cell Death and Disease.

[6]  D. Butterfield,et al.  Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre‐clinical AD, amnestic mild cognitive impairment and late‐stage AD , 2015, Journal of neurochemistry.

[7]  Xue Fang,et al.  Insulin-like growth factor-binding protein 7 is up-regulated during EAE and inhibits the differentiation of oligodendrocyte precursor cells. , 2015, Biochemical and biophysical research communications.

[8]  D. Jezova,et al.  Hyperinsulinemia in newly diagnosed patients with multiple sclerosis , 2015, Metabolic Brain Disease.

[9]  H. Bellen,et al.  Huntingtin Functions as a Scaffold for Selective Macroautophagy , 2015, Nature Cell Biology.

[10]  J. Gómez-Ariza,et al.  Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer's disease , 2015, Electrophoresis.

[11]  B. Davidson,et al.  Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes , 2015, Neuron.

[12]  Eunju Choi,et al.  Influencing effect of non-motor symptom clusters on quality of life in Parkinson's disease , 2014, Journal of the Neurological Sciences.

[13]  N. Rosenthal,et al.  Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease , 2014, EMBO molecular medicine.

[14]  M. MacDonald,et al.  Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington’s disease , 2014, Science Signaling.

[15]  E. Bézard,et al.  Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives , 2014, The Lancet.

[16]  W. Pan,et al.  Leukocyte infiltration into spinal cord of EAE mice is attenuated by removal of endothelial leptin signaling , 2014, Brain, Behavior, and Immunity.

[17]  Shile Huang,et al.  Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease. , 2014, Cellular signalling.

[18]  E. Bézard,et al.  Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification? , 2014, Progress in Neurobiology.

[19]  M. Hayden,et al.  IGF-1 Intranasal Administration Rescues Huntington's Disease Phenotypes in YAC128 Mice , 2014, Molecular Neurobiology.

[20]  Nan Wang,et al.  Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington's disease , 2014, Nature Medicine.

[21]  A. Teixeira,et al.  Circulating levels of adipokines in Parkinson's disease , 2014, Journal of the Neurological Sciences.

[22]  Ariel Miller,et al.  Revised diagnostic criteria of multiple sclerosis. , 2014, Autoimmunity reviews.

[23]  R. Resende,et al.  Protective Effect of Leptin and Ghrelin against Toxicity Induced by Amyloid‐β Oligomers in a Hypothalamic cell Line , 2014, Journal of neuroendocrinology.

[24]  Ming Lu,et al.  Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice , 2014, Experimental Neurology.

[25]  A. Kowaltowski,et al.  Dietary restriction in cerebral bioenergetics and redox state☆ , 2014, Redox biology.

[26]  Hyoung-Gon Lee,et al.  Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance , 2014, Journal of neurochemistry.

[27]  F. Carbone,et al.  Regulatory T cell proliferative potential is impaired in human autoimmune disease , 2013, Nature Medicine.

[28]  T. Foltynie,et al.  Exenatide and the treatment of patients with Parkinson's disease. , 2013, The Journal of clinical investigation.

[29]  M. Schwartz,et al.  Leptin and the brain: then and now. , 2013, The Journal of clinical investigation.

[30]  J. Potashkin,et al.  Shared dysregulated pathways lead to Parkinson's disease and diabetes. , 2013, Trends in molecular medicine.

[31]  M. T. Pellecchia,et al.  Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson’s disease , 2013, Journal of Neurology.

[32]  C. Koebnick,et al.  Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome , 2013, Neurology.

[33]  T. Foltynie,et al.  Parkinson's disease, insulin resistance and novel agents of neuroprotection. , 2013, Brain : a journal of neurology.

[34]  Jianqing Ding,et al.  Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy , 2013, Journal of Neuroimmune Pharmacology.

[35]  T. Dawson,et al.  Development and Characterization of a New Parkinson's Disease Model Resulting from Impaired Autophagy , 2012, The Journal of Neuroscience.

[36]  Feng Guo,et al.  Acylated ghrelin protects hippocampal neurons in pilocarpine-induced seizures of immature rats by inhibiting cell apoptosis , 2012, Molecular Biology Reports.

[37]  A. Pisani,et al.  The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life , 2012, Journal of Neurology.

[38]  S. Correia,et al.  Metabolic Alterations Induced by Sucrose Intake and Alzheimer’s Disease Promote Similar Brain Mitochondrial Abnormalities , 2012, Diabetes.

[39]  J. Schneider,et al.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. , 2012, The Journal of clinical investigation.

[40]  D. Munoz,et al.  An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. , 2012, The Journal of clinical investigation.

[41]  T. Olsson,et al.  High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women , 2012, Multiple sclerosis.

[42]  C. Tassorelli,et al.  Neuroprotection by leptin in a rat model of permanent cerebral ischemia: effects on STAT3 phosphorylation in discrete cells of the brain , 2011, Cell Death and Disease.

[43]  I. Parker,et al.  Single-channel Ca2+ imaging implicates Aβ1–42 amyloid pores in Alzheimer’s disease pathology , 2011, The Journal of cell biology.

[44]  G. Petit,et al.  IGF-1 protects against diabetic features in an in vivo model of Huntington's disease , 2011, Experimental Neurology.

[45]  A. Paul,et al.  Adipocytokines and CD34+ Progenitor Cells in Alzheimer's Disease , 2011, PloS one.

[46]  L. Fratiglioni,et al.  Midlife overweight and obesity increase late-life dementia risk , 2011, Neurology.

[47]  J. Mauer,et al.  Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. , 2011, Cell metabolism.

[48]  P. Worley,et al.  The mammalian Target of Rapamycin (mTOR) regulates T helper cell differentiation through the selective activation of mTORC1 and mTORC2 signaling , 2011, Nature Immunology.

[49]  P. Chieffi,et al.  Leptin Modulates the Survival of Autoreactive CD4+ T Cells through the Nutrient/Energy-Sensing Mammalian Target of Rapamycin Signaling Pathway , 2010, The Journal of Immunology.

[50]  T. Horvath,et al.  An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness. , 2010, Immunity.

[51]  A. Hofman,et al.  Insulin metabolism and the risk of Alzheimer disease , 2010, Neurology.

[52]  A. Bachoud-Lévi,et al.  High insulinlike growth factor I is associated with cognitive decline in Huntington disease , 2010, Neurology.

[53]  F. Mashayekhi,et al.  Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease , 2010, Journal of Clinical Neuroscience.

[54]  Min Zhang,et al.  Insulin like growth factor-1 prevents 1-mentyl-4-phenylphyridinium-induced apoptosis in PC12 cells through activation of glycogen synthase kinase-3beta. , 2010, Toxicology.

[55]  G. Martino,et al.  Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation , 2010, Journal of Neuroimmunology.

[56]  J. Dixon,et al.  The effect of obesity on health outcomes , 2010, Molecular and Cellular Endocrinology.

[57]  E. Kahana,et al.  Multiple sclerosis: geoepidemiology, genetics and the environment. , 2010, Autoimmunity reviews.

[58]  D. Berg,et al.  Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  V. Longo,et al.  Calorie restriction and cancer prevention: metabolic and molecular mechanisms. , 2010, Trends in pharmacological sciences.

[60]  H. Pijl,et al.  Growth hormone and ghrelin secretion are associated with clinical severity in Huntington’s disease , 2010, European journal of neurology.

[61]  R. Datta,et al.  Ghrelin in the regulation of body weight and metabolism , 2010, Frontiers in Neuroendocrinology.

[62]  Lloyd A Greene,et al.  Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.

[63]  Sang-Tae Kim,et al.  A novel mTOR activating protein protects dopamine neurons against oxidative stress by repressing autophagy related cell death , 2010, Journal of neurochemistry.

[64]  Sudha Seshadri,et al.  Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. , 2009, JAMA.

[65]  Eva L Feldman,et al.  Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. , 2009, Endocrinology.

[66]  R. Roth,et al.  Ghrelin Promotes and Protects Nigrostriatal Dopamine Function via a UCP2-Dependent Mitochondrial Mechanism , 2009, The Journal of Neuroscience.

[67]  T. Chitnis,et al.  Body size and risk of MS in two cohorts of US women , 2009, Neurology.

[68]  L. Blonde,et al.  The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies , 2009, Diabetes, obesity & metabolism.

[69]  K. Chan,et al.  Mitochondrial Uncoupling Protein-2 (UCP2) Mediates Leptin Protection Against MPP+ Toxicity in Neuronal Cells , 2009, Neurotoxicity Research.

[70]  T. Yamamura,et al.  Suppression of Experimental Autoimmune Encephalomyelitis by Ghrelin1 , 2009, The Journal of Immunology.

[71]  P. Greengard,et al.  Inhibition of mTOR Signaling in Parkinson’s Disease Prevents l-DOPA–Induced Dyskinesia , 2009, Science Signaling.

[72]  Sterling C. Johnson,et al.  Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys , 2009, Science.

[73]  N. Pedersen,et al.  Overweight in midlife and risk of dementia: a 40-year follow-up study , 2009, International Journal of Obesity.

[74]  M. Oh,et al.  Neuroprotective Effect of Ghrelin in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson’s Disease by Blocking Microglial Activation , 2009, Neurotoxicity Research.

[75]  Steven J. Greco,et al.  Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. , 2009, Biochemical and biophysical research communications.

[76]  Yinghe Hu,et al.  Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42) , 2008, Neuroscience Letters.

[77]  L. Piccio,et al.  Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis , 2008, Journal of leukocyte biology.

[78]  Jan Petter Larsen,et al.  Epidemiology of Parkinson’s disease , 2008, Journal of Neurology.

[79]  B. Bloem,et al.  Weight loss in neurodegenerative disorders , 2008, Journal of Neurology.

[80]  E. Oster,et al.  Fear of health insurance loss among individuals at risk for Huntington disease , 2008, American journal of medical genetics. Part A.

[81]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[82]  J. Trojanowski,et al.  Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.

[83]  B. Trapp,et al.  Multiple sclerosis: an immune or neurodegenerative disorder? , 2008, Annual review of neuroscience.

[84]  E. Masliah,et al.  The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.

[85]  C. Davie.  A review of Parkinson's disease. , 2008, British medical bulletin.

[86]  Christine Stadelmann,et al.  Cortical pathology in multiple sclerosis , 2008, Current opinion in neurology.

[87]  I. Ziabreva,et al.  Mitochondrial defects in acute multiple sclerosis lesions , 2008, Brain : a journal of neurology.

[88]  Xiao-Ping Wang,et al.  Alzheimer’s disease: epidemiology, genetics, and beyond , 2008, Neuroscience bulletin.

[89]  A. Quesada,et al.  PI3 kinase/Akt activation mediates estrogen and IGF‐1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease , 2008, Developmental neurobiology.

[90]  V. Kostic,et al.  Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. , 2008, Archives of neurology.

[91]  C. Svendsen,et al.  Human neural progenitor cells over-expressing IGF-1 protect dopamine neurons and restore function in a rat model of Parkinson's disease , 2008, Experimental Neurology.

[92]  V. Tomassini,et al.  The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing–remitting multiple sclerosis , 2007, Journal of Neuroimmunology.

[93]  Xiao-Ming Yin,et al.  Leptin Protects against 6-Hydroxydopamine-induced Dopaminergic Cell Death via Mitogen-activated Protein Kinase Signaling* , 2007, Journal of Biological Chemistry.

[94]  M. White,et al.  Brain IRS2 Signaling Coordinates Life Span and Nutrient Homeostasis , 2007, Science.

[95]  Bruce D. Trapp,et al.  Pathogenesis of axonal and neuronal damage in multiple sclerosis , 2007, Neurology.

[96]  Danielle A. Simmons,et al.  Brain-Derived Neurotrophic Factor Restores Synaptic Plasticity in a Knock-In Mouse Model of Huntington's Disease , 2007, The Journal of Neuroscience.

[97]  P. Wolf,et al.  Relation of obesity to cognitive function: importance of central obesity and synergistic influence of concomitant hypertension. The Framingham Heart Study. , 2007, Current Alzheimer research.

[98]  T. Arendt,et al.  Effect of Pseudophosphorylation and Cross-linking by Lipid Peroxidation and Advanced Glycation End Product Precursors on Tau Aggregation and Filament Formation* , 2007, Journal of Biological Chemistry.

[99]  You-Wen He,et al.  Maintaining T Lymphocyte Homeostasis: Another Duty of Autophagy , 2007, Autophagy.

[100]  D. Cardinali,et al.  Immune response after experimental allergic encephalomyelitis in rats subjected to calorie restriction , 2007, Journal of Neuroinflammation.

[101]  You-Wen He,et al.  A critical role for the autophagy gene Atg5 in T cell survival and proliferation , 2007, The Journal of experimental medicine.

[102]  Chang-Shin Park,et al.  Leptin inhibits 1-methyl-4-phenylpyridinium-induced cell death in SH-SY5Y cells , 2006, Neuroscience Letters.

[103]  Simon C Watkins,et al.  Autophagy Is Induced in CD4+ T Cells and Important for the Growth Factor-Withdrawal Cell Death1 , 2006, The Journal of Immunology.

[104]  Å. Petersén,et al.  Hypothalamic–endocrine aspects in Huntington's disease , 2006, The European journal of neuroscience.

[105]  Kewei Chen,et al.  Brain abnormalities in human obesity: A voxel-based morphometric study , 2006, NeuroImage.

[106]  Hideyuki Okano,et al.  Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice , 2006, Nature.

[107]  J. Rothman,et al.  Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway , 2006, The Journal of cell biology.

[108]  B. Trapp,et al.  NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia , 2006, Nature.

[109]  P. Chieffi,et al.  Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis. , 2006, The Journal of clinical investigation.

[110]  Sterling C. Johnson,et al.  The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study , 2005, BMC neurology.

[111]  M. Reger,et al.  Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone: A Preliminary Study , 2005 .

[112]  Hilkka Soininen,et al.  Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. , 2005, Archives of neurology.

[113]  D. Bennett,et al.  Change in body mass index and risk of incident Alzheimer disease , 2005, Neurology.

[114]  N. Rothwell,et al.  Interleukin-1 and neuronal injury , 2005, Nature Reviews Immunology.

[115]  P. Bickford,et al.  Brain-Derived Neurotrophic Factor Is Required for the Establishment of the Proper Number of Dopaminergic Neurons in the Substantia Nigra Pars Compacta , 2005, The Journal of Neuroscience.

[116]  Karen Marder,et al.  Energy balance in early-stage Huntington disease. , 2005, The American journal of clinical nutrition.

[117]  John A Matochik,et al.  Effect of leptin replacement on brain structure in genetically leptin-deficient adults. , 2005, The Journal of clinical endocrinology and metabolism.

[118]  Kristine Yaffe,et al.  Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study , 2005, BMJ : British Medical Journal.

[119]  V. De Rosa,et al.  Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[120]  A. Dürr,et al.  Akt is altered in an animal model of Huntington's disease and in patients , 2005, The European journal of neuroscience.

[121]  N. Wilczak,et al.  Serum levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in relapsing and primary progressive multiple sclerosis , 2005, Multiple Sclerosis.

[122]  Tamas L. Horvath,et al.  Uncoupling Protein-2 Is Critical for Nigral Dopamine Cell Survival in a Mouse Model of Parkinson's Disease , 2005, The Journal of Neuroscience.

[123]  D. Cardinali,et al.  Experimental allergic encephalomyelitis in male Lewis rats subjected to calorie restriction , 2004, Journal of Physiology and Biochemistry.

[124]  F. Pi‐Sunyer,et al.  Obesity‐related leptin regulates Alzheimer's Aβ , 2004 .

[125]  G. Bates,et al.  Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.

[126]  F. Casanueva,et al.  Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.

[127]  G. Mengod,et al.  Brain-Derived Neurotrophic Factor Regulates the Onset and Severity of Motor Dysfunction Associated with Enkephalinergic Neuronal Degeneration in Huntington's Disease , 2004, The Journal of Neuroscience.

[128]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[129]  P. Gluckman,et al.  N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats , 2004, Neuroreport.

[130]  F. Casanueva,et al.  Orexin A suppresses in vivo GH secretion. , 2004, European journal of endocrinology.

[131]  Patrick R Hof,et al.  Diet‐induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[132]  C. Blakemore,et al.  Environmental Enrichment Rescues Protein Deficits in a Mouse Model of Huntington's Disease, Indicating a Possible Disease Mechanism , 2004, The Journal of Neuroscience.

[133]  I. Torres-Aleman,et al.  Role of insulin-like growth factor I signaling in neurodegenerative diseases , 2004, Journal of Molecular Medicine.

[134]  H. Schiöth,et al.  Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin. , 2004, Biochemical and biophysical research communications.

[135]  M. MacDonald,et al.  Enhanced Akt Signaling Is an Early Pro-survival Response That Reflects N-Methyl-D-aspartate Receptor Activation in Huntington's Disease Knock-in Striatal Cells* , 2003, Journal of Biological Chemistry.

[136]  Cecil M. Burchfiel,et al.  Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study , 2003, Journal of Neurology.

[137]  W. Kuziel,et al.  Chemokine Expression by Glial Cells Directs Leukocytes to Sites of Axonal Injury in the CNS , 2003, The Journal of Neuroscience.

[138]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[139]  N. Greig,et al.  The glucagon-like peptides: a double-edged therapeutic sword? , 2003, Trends in pharmacological sciences.

[140]  P. Tonali,et al.  Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta , 2003, Journal of Neuroimmunology.

[141]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[142]  B. Ransom,et al.  Functional Hemichannels in Astrocytes: A Novel Mechanism of Glutamate Release , 2003, The Journal of Neuroscience.

[143]  Miguel A Hernán,et al.  Weight loss in Parkinson's disease , 2003, Annals of neurology.

[144]  S. B. Evans,et al.  Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat , 2003, Brain Research.

[145]  C. Barnes,et al.  Impact of aging on hippocampal function: plasticity, network dynamics, and cognition , 2003, Progress in Neurobiology.

[146]  R. Lechler,et al.  Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses. , 2003, The Journal of clinical investigation.

[147]  Ole A. Andreassen,et al.  Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression , 2002, Neurobiology of Disease.

[148]  K. Marder,et al.  Weight loss in early stage of Huntington’s disease , 2002, Neurology.

[149]  C. Tanner,et al.  Midlife adiposity and the future risk of Parkinson’s disease , 2002, Neurology.

[150]  D. Galimberti,et al.  Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. , 2002, The Journal of endocrinology.

[151]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[152]  E. Jéquier.  Leptin Signaling, Adiposity, and Energy Balance , 2002, Annals of the New York Academy of Sciences.

[153]  Jorge R. Oksenberg,et al.  Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis , 2002, Nature Medicine.

[154]  Abraham Weizman,et al.  Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson’s disease , 2001, Neuroscience Letters.

[155]  C. Adler,et al.  Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss , 2001, Movement disorders : official journal of the Movement Disorder Society.

[156]  C. Brosnan,et al.  Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. , 2001, The American journal of pathology.

[157]  Graham M Lord,et al.  Requirement for Leptin in the Induction and Progression of Autoimmune Encephalomyelitis1 , 2001, The Journal of Immunology.

[158]  A. Pérez-Samartín,et al.  The link between excitotoxic oligodendroglial death and demyelinating diseases , 2001, Trends in Neurosciences.

[159]  Elena Cattaneo,et al.  Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.

[160]  B. Levin.  Glucose-regulated dopamine release from substantia nigra neurons , 2000, Brain Research.

[161]  I. Ferrer,et al.  Brain-derived neurotrophic factor in Huntington disease , 2000, Brain Research.

[162]  E. Ravussin,et al.  Higher sedentary energy expenditure in patients with Huntington's disease , 2000, Annals of neurology.

[163]  Y. Stern,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[164]  H. Ichinose,et al.  Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease , 1999, Neuroscience Letters.

[165]  J C Reed,et al.  Mitochondria and apoptosis. , 1998, Science.

[166]  N. Taylor,et al.  Sleep disturbance and Huntingdon's disease , 1997, British Journal of Psychiatry.

[167]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[168]  C. Mantzoros,et al.  Human leptin levels are pulsatile and inversely related to pituitary–ardenal function , 1997, Nature Medicine.

[169]  R. Hohlfeld,et al.  Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. , 1997, Brain : a journal of neurology.

[170]  P. Brundin,et al.  Effects of α-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionate , 1996, Neuroscience.

[171]  A. McCall,et al.  Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study , 1996, Brain Research.

[172]  K. Heidenreich,et al.  Growth Factors Rescue Embryonic Dopamine Neurons from Programmed Cell Death , 1996, Experimental Neurology.

[173]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[174]  K. Schmader,et al.  Weight Change in Alzheimer's Disease , 1996, Journal of the American Geriatrics Society.

[175]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[176]  I. Reynolds,et al.  Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[177]  C. Portera-Cailliau,et al.  Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[178]  K. Hirayama,et al.  Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease , 1994, Acta Neuropathologica.

[179]  A. Matsumoto,et al.  Aberrant proteolysis of the beta-amyloid precursor protein in familial Alzheimer's disease lymphoblastoid cells. , 1993, European journal of biochemistry.

[180]  S. Estus,et al.  Production of the Alzheimer amyloid beta protein by normal proteolytic processing. , 1992, Science.

[181]  R. Lindsay,et al.  Brain‐Derived Neurotrophic Factor Protects Dopamine Neurons Against 6‐Hydroxydopamine and N‐Methyl‐4‐Phenylpyridinium Ion Toxicity: Involvement of the Glutathione System , 1992, Journal of neurochemistry.

[182]  R. Roos,et al.  Weight loss in Huntington's disease. , 1992, Archives of neurology.

[183]  P. Cras,et al.  Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[184]  A. Tomkins,et al.  Increased energy expenditure in Parkinson's disease. , 1990, BMJ.

[185]  T. Gunter,et al.  Mechanisms by which mitochondria transport calcium. , 1990, The American journal of physiology.

[186]  A. Guidotti,et al.  Delayed increase of Ca2+ influx elicited by glutamate: role in neuronal death. , 1989, Molecular pharmacology.

[187]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[188]  K. Jellinger,et al.  Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. , 1973, Journal of the neurological sciences.

[189]  M. Tripathi,et al.  Aberrant Autophagy and Parkinsonism: Does Correction Rescue from Disease Progression? , 2014, Molecular Neurobiology.

[190]  A. Björklund,et al.  mTOR inhibition alleviates L-DOPA-induced dyskinesia in parkinsonian rats. , 2013, Journal of Parkinson's disease.

[191]  S. Correia,et al.  Type 2 diabetic and Alzheimer's disease mice present similar behavioral, cognitive, and vascular anomalies. , 2013, Journal of Alzheimer's disease : JAD.

[192]  Stuart Maudsley,et al.  Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. , 2012, Current Alzheimer research.

[193]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[194]  Steven J. Greco,et al.  Leptin reduces pathology and improves memory in a transgenic mouse model of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[195]  H. Ischiropoulos,et al.  Molecular Neurodegeneration BioMed Central Review , 2009 .

[196]  N. Wilczak,et al.  The insulin-like growth factor system in multiple sclerosis. , 2007, International review of neurobiology.

[197]  Eunhee Kim,et al.  Ghrelin inhibits apoptosis in hypothalamic neuronal cells during oxygen-glucose deprivation. , 2007, Endocrinology.

[198]  N. Aziz,et al.  Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications , 2007, Reviews in the neurosciences.

[199]  J. Wands,et al.  Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? , 2005, Journal of Alzheimer's disease : JAD.

[200]  R Sandyk,et al.  The relationship between diabetes mellitus and Parkinson's disease. , 1993, The International journal of neuroscience.

[201]  Z. Andrews,et al.  Therapeutic Advances in Endocrinology and Metabolism Review , 2022 .

[202]  J. Flier,et al.  Regulation of neuronal and glial proteins by leptin: implications for brain development. , 1999, Endocrinology.